Latest News and Press Releases

NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Aarhus, Denmark, 14 December 2022 – NMD Pharma A/S, a...

NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Aarhus, Denmark, 14 December 2022 – NMD Pharma A/S, a...

NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis Data provides first clinical proof of the mechanism of action of NMD Pharma’s...

NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis Data provides first clinical proof of the mechanism of action of NMD Pharma’s...

FDA grants Orphan Drug Designation for NMD670 for the Treatment of Myasthenia Gravis Aarhus, Denmark, 27 September 2022 – NMD Pharma A/S, a clinical stage biotech company developing first-in-class...

PRESS RELEASE NMD Pharma appoints Dr. Jorge A. Quiroz as EVP, Chief Medical Officer Dr. Quiroz brings extensive US and European clinical and regulatory expertiseRole will be based in Boston,...

PRESS RELEASE NMD Pharma expands its US presence Creates US subsidiary and increases US R&D and staff recruitment activity Aarhus, Denmark, 3 May 2022 – NMD Pharma A/S, a clinical stage biotech...

NMD Pharma Raises €35 Million in a new Financing - New investor Jeito Capital joins current NMD Pharma investors - Proceeds will be used to progress lead clinical programs, expand the number of...

NMD Pharma Raises €35 Million in a new Financing - New investor Jeito Capital joins current NMD Pharma investors - Proceeds will be used to progress lead clinical programs, expand the number of...

PRESS RELEASE NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease The international observational study will be conducted in collaboration with Aarhus University and...